Literature DB >> 11745385

Requirement for CD28 co-stimulation is lower in SHP-1-deficient T cells.

J G Sathish1, K G Johnson, F G LeRoy, K J Fuller, M B Hallett, P Brennan, L K Borysiewicz, M J Sims, R J Matthews.   

Abstract

This study provides biochemical and functional evidence pertaining to the role of the intracellular protein tyrosine phosphatase, SHP-1, in influencing thresholds for TCR activation. Although the loss of SHP-1 in thymocytes from motheaten mice had minimal effects on the initial rise of cytosolic Ca(2+) concentration following TCR triggering, the post-stimulation equilibrium levels of Ca(2+) were consistently elevated. In keeping with a SHP-1 effect on PLCgamma function, IP3 generation was increased in SHP-1 deficient thymocytes. Importantly, we demonstrate that loss of SHP-1 results in a relaxation of the normally stringent co-stimulatory requirements for IL-2 production. SHP-1 deficient single-positive CD4(+) thymocytes revealed a significantly enhanced capacity to produce IL-2 in response to anti-CD3 stimulation alone. In contrast, the simultaneous triggering of CD3 and CD28 was required for equivalent IL-2 production in control single-positive CD4(+) thymocytes. Furthermore, SHP-1 deficient thymocytes generated an increased and prolonged proliferative response to anti-CD3 stimulation alone. In addition, the simultaneous triggering of CD28 and CD3 resulted in equivalent proliferative responses in SHP-1-deficient and control thymocytes, suggesting that a strong co-stimulatory signal is able to override the effect of SHP-1 loss on TCR hyperresponsiveness. Collectively, these results suggest that SHP-1, rather than acting directly on TCR signaling, may indirectly raise thresholds for TCR triggering by modulating co-stimulatory signals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745385     DOI: 10.1002/1521-4141(200112)31:12<3649::aid-immu3649>3.0.co;2-8

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

1.  CD28 co-signaling in the adaptive immune response.

Authors:  Pavel Riha; Christopher E Rudd
Journal:  Self Nonself       Date:  2010-07-12

2.  T Cells Deficient in the Tyrosine Phosphatase SHP-1 Resist Suppression by Regulatory T Cells.

Authors:  Emily R Mercadante; Ulrike M Lorenz
Journal:  J Immunol       Date:  2017-05-26       Impact factor: 5.422

3.  Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus.

Authors:  Christina G Katsiari; Vasileios C Kyttaris; Yuang-Taung Juang; George C Tsokos
Journal:  J Clin Invest       Date:  2005-10-13       Impact factor: 14.808

4.  SHP-1 in T cells limits the production of CD8 effector cells without impacting the formation of long-lived central memory cells.

Authors:  Carla C Fowler; Lily I Pao; Joseph N Blattman; Philip D Greenberg
Journal:  J Immunol       Date:  2010-08-09       Impact factor: 5.422

Review 5.  E proteins in lymphocyte development and lymphoid diseases.

Authors:  Ian Belle; Yuan Zhuang
Journal:  Curr Top Dev Biol       Date:  2014       Impact factor: 4.897

Review 6.  Breaking Free of Control: How Conventional T Cells Overcome Regulatory T Cell Suppression.

Authors:  Emily R Mercadante; Ulrike M Lorenz
Journal:  Front Immunol       Date:  2016-05-18       Impact factor: 7.561

Review 7.  Shp1 in Solid Cancers and Their Therapy.

Authors:  Alessia Varone; Daniela Spano; Daniela Corda
Journal:  Front Oncol       Date:  2020-06-11       Impact factor: 6.244

Review 8.  CD28 and CTLA-4 coreceptor expression and signal transduction.

Authors:  Christopher E Rudd; Alison Taylor; Helga Schneider
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

9.  Purity of transferred CD8(+) T cells is crucial for safety and efficacy of combinatorial tumor immunotherapy in the absence of SHP-1.

Authors:  H Angharad Watson; Garry Dolton; Julia Ohme; Kristin Ladell; Miriam Vigar; Sophie Wehenkel; James Hindley; Rebar N Mohammed; Kelly Miners; Rhys A Luckwell; David A Price; R James Matthews; Ann Ager
Journal:  Immunol Cell Biol       Date:  2016-07-19       Impact factor: 5.126

Review 10.  SHP-1: the next checkpoint target for cancer immunotherapy?

Authors:  H Angharad Watson; Sophie Wehenkel; James Matthews; Ann Ager
Journal:  Biochem Soc Trans       Date:  2016-04-15       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.